A JAKi in GCA: Phase 3 Results Through 2 Years

Save

Listen as rheumatologists Dr. Anisha Dua and Dr. Ben Boone discuss the latest efficacy and safety results over 2 years from a Phase 3 trial in GCA, including remission, flares, and glucocorticoid use in patients continuing vs withdrawing a JAKi"

Sjögren’s Disease – What Are You Missing?

Save

What could you be missing in Sjögren's disease? Explore hypothetical patient cases with atypical presentations, systemic manifestations, and overlooked symptoms. Gain expert insights and practical tips for clinical assessment from Dr Shereen Mahmood and learn how the ESSDAI can help you measure disease activity.

A JAKi CHAT: Shared Decision-Making in RA

Save

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

ILD Treatment and Guidelines

Save

Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.

Structural damage progression in active PsA

Save

Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data

Navigating the Path to SLE Remission

Save

Watch rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.

GCA: Case by Case

Save

Dive into 4 hypothetical case studies that reveal the diverse and often complex presentations of giant cell arteritis (GCA). Each case is guided by expert commentary from Dr Michael Putman, where he offers practical insights and clinical pearls to enhance your therapeutic strategies for this multifaceted condition.

Debunked. Expert perspectives on Sjögren’s Disease myths

Save

How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.

Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA

Save

Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor's potential role in managing patients with PsA.

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis

Save

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Lupus Nephritis

Save

View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.

Biomarkers in RA

Save

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.